Five year data presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting show that erbitux (cetuximab), combined with radiation, increases overall survival in patients with locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN).
Filed under: Uncategorized | Tagged: BMS, cetuximab, erbitux, HER1, ImClone, Merck KGaA, Merck-Serono | Comments Off
AVEO Pharmaceuticals has initiated a Phase 1 clinical trial of its HGF MAb SCH900105 (AV-299) in patients with relapsed or refractory solid tumors or lymphoma.This triggers a $3.0 million milestone payment from Schering Plough to AVEO.
Filed under: Uncategorized | Tagged: AV-299, AV299, AVEO, c-met, cmet, SCH-900105, SCH900105, Schering, Schering Plough | Comments Off
iCo Therapeutics have provided interim results from its phase I, trial of c-Raf antisense agent iCo-007 in patients with diffuse diabetic macular edema (DME).No adverse effects were observed and the trial will progress to a third cohort
Filed under: kinase | Tagged: antisense, c-raf, craf, iCo, iCo therapeutics, ISIS, kinase | Comments Off
